Cutaneous malignancies (including melanoma, squamous cell carcinoma of the skin, and basal cell carcinoma) with treatment with PD-1 antibody have a high incidence of dermatitis as to 43%, and the incidence of head and neck cancer was also increased to 20%, both significantly higher than that of lung cancer patients. Here, PDCD1 is linked to skin disorder.